On the public citation graph

Nucleos(t)ide Analogues for Reducing Hepatocellular Carcinoma in Chronic Hepatitis B Patients: A Systematic Review and Meta-Analysis

https://doi.org/10.5009/gnl18546
0 signed · 112 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

1 of the 60 references listed on this page is in the Retraction Watch database as retracted (export 2026-10-21): 10.1001/jamaoncol.2018.4070 (notice 2019-04-25).

Dataset join, best-effort; this page does not check the publisher record. Retraction Watch data via Crossref Labs, used with credit; OpenCitations Index (CC0) and Meta (CC BY 4.0); dataset doi:10.7910/DVN/WT8VOA (CC BY 4.0).

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1001/jama.2018.3795openalex-snapshot
Chronic Hepatitis B Infection
inferredcites →https://doi.org/10.1001/jamaoncol.2018.4039openalex-snapshot
Tenofovir vs Entecavir for Hepatocellular Carcinoma Prevention in Patients With Chronic Hepatitis B
inferredcites →https://doi.org/10.1001/jamaoncol.2018.4070openalex-snapshot
Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B
inferredcites →https://doi.org/10.1002/cncr.29159openalex-snapshot
Nucleos(t)ide analogues associated with a reduced risk of hepatocellular carcinoma in hepatitis B patients: A population‐based cohort study
inferredcites →https://doi.org/10.1002/hep.25937openalex-snapshot
Prevention of hepatitis B virus–related hepatocellular carcinoma with antiviral therapy
inferredcites →https://doi.org/10.1002/hep.26180openalex-snapshot
Long-term entecavir treatment reduces hepatocellular carcinoma incidence in patients with hepatitis B virus infection
inferredcites →https://doi.org/10.1002/hep.28156openalex-snapshot
AASLD guidelines for treatment of chronic hepatitis B
inferredcites →https://doi.org/10.1002/hep.29800openalex-snapshot
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
inferredcites →https://doi.org/10.1007/s10620-017-4448-7openalex-snapshot
Effectiveness and Safety of Entecavir or Tenofovir in a Spanish Cohort of Chronic Hepatitis B Patients: Validation of the Page-B Score to Predict Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1007/s10654-010-9491-zopenalex-snapshot
Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses
inferredcites →https://doi.org/10.1007/s12029-017-9959-0openalex-snapshot
Global Epidemiology of Hepatocellular Carcinoma (HCC Epidemiology)
inferredcites →https://doi.org/10.1007/s12072-012-9365-4openalex-snapshot
Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update
inferredcites →https://doi.org/10.1007/s40265-017-0754-9openalex-snapshot
Tenofovir Alafenamide: A Review in Chronic Hepatitis B
inferredcites →https://doi.org/10.1016/0197-2456(95)00134-4openalex-snapshot
Assessing the quality of reports of randomized clinical trials: Is blinding necessary?
inferredcites →https://doi.org/10.1016/j.antiviral.2015.09.011openalex-snapshot
Hepatitis B virus reverse transcriptase – Target of current antiviral therapy and future drug development
inferredcites →https://doi.org/10.1016/j.cgh.2012.10.003openalex-snapshot
Long-term Efficacy and Safety of Lamivudine, Entecavir, and Tenofovir for Treatment of Hepatitis B Virus–Related Cirrhosis
inferredcites →https://doi.org/10.1016/j.cgh.2013.01.026openalex-snapshot
Reduction of Hepatitis B Surface Antigen and Covalently Closed Circular DNA by Nucleos(t)ide Analogues of Different Potency
inferredcites →https://doi.org/10.1016/j.coviro.2011.10.008openalex-snapshot
Interferon-stimulated genes and their antiviral effector functions
inferredcites →https://doi.org/10.1016/j.jfma.2016.08.006openalex-snapshot
Long-term outcomes of hepatitis B virus-related cirrhosis treated with nucleos(t)ide analogs
inferredcites →https://doi.org/10.1016/j.jhep.2009.04.013openalex-snapshot
Modeling the cost-effectiveness of different oral antiviral therapies in patients with chronic hepatitis B
inferredcites →https://doi.org/10.1016/j.jhep.2012.02.010openalex-snapshot
EASL Clinical Practice Guidelines: Management of chronic hepatitis B virus infection
inferredcites →https://doi.org/10.1016/j.jhep.2015.01.002openalex-snapshot
Risk of hepatocellular carcinoma in chronic hepatitis B: Assessment and modification with current antiviral therapy
inferredcites →https://doi.org/10.1016/j.jhep.2016.02.021openalex-snapshot
Mechanisms of HBV-induced hepatocellular carcinoma
inferredcites →https://doi.org/10.1016/s1665-2681(19)31354-7openalex-snapshot
Epidemiology of hepatocellular carcinoma in sub-Saharan Africa
inferredcites →https://doi.org/10.1053/j.gastro.2010.06.042openalex-snapshot
Tenofovir and Entecavir Are the Most Effective Antiviral Agents for Chronic Hepatitis B: A Systematic Review and Bayesian Meta-analyses
inferredcites →https://doi.org/10.1053/j.gastro.2014.02.033openalex-snapshot
Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine
inferredcites →https://doi.org/10.1053/j.gastro.2014.03.048openalex-snapshot
Association of Nucleos(t)ide Analogue Therapy With Reduced Risk of Hepatocellular Carcinoma in Patients With Chronic Hepatitis B—A Nationwide Cohort Study
inferredcites →https://doi.org/10.1056/nejmoa033364openalex-snapshot
Lamivudine for Patients with Chronic Hepatitis B and Advanced Liver Disease
inferredcites →https://doi.org/10.1093/infdis/jiv572openalex-snapshot
Hepatitis B Virus (HBV) Core-Related Antigen During Nucleos(t)ide Analog Therapy Is Related to Intra-hepatic HBV Replication and Development of Hepatocellular Carcinoma
inferredcites →https://doi.org/10.1093/jac/dku041openalex-snapshot
Determinants of hepatocellular carcinoma in cirrhotic patients treated with nucleos(t)ide analogues for chronic hepatitis B
inferredcites →https://doi.org/10.1111/1469-0691.12220openalex-snapshot
A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match–control study
inferredcites →https://doi.org/10.1111/apt.12990openalex-snapshot
The incidence of hepatocellular carcinoma is reduced in patients with chronic hepatitis B on long‐term nucleos(t)ide analogue therapy
inferredcites →https://doi.org/10.1111/apt.13548openalex-snapshot
Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B‐related hepatocellular carcinoma
inferredcites →https://doi.org/10.1111/apt.13707openalex-snapshot
Long‐term lamivudine therapy in chronic hepatitis B
inferredcites →https://doi.org/10.1111/apt.14015openalex-snapshot
Long‐term use of oral nucleos(t)ide analogues for chronic hepatitis B does not increase cancer risk – a cohort study of 44 494 subjects
inferredcites →https://doi.org/10.1111/j.1365-2036.2008.03816.xopenalex-snapshot
Meta‐analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma
inferredcites →https://doi.org/10.1111/j.1751-2980.2009.00375.xopenalex-snapshot
A 7‐year study of lamivudine therapy for hepatitis B virus e antigen‐positive chronic hepatitis B patients in China
inferredcites →https://doi.org/10.1111/j.1872-034x.2011.00785.xopenalex-snapshot
Long‐term outcome and hepatocellular carcinoma development in chronic hepatitis B or cirrhosis patients after nucleoside analog treatment with entecavir or lamivudine
inferredcites →https://doi.org/10.1111/jebm.12141openalex-snapshot
The methodological quality assessment tools for preclinical and clinical studies, systematic review and meta‐analysis, and clinical practice guideline: a systematic review
inferredcites →https://doi.org/10.1111/jgh.12220openalex-snapshot
Update on epidemiology of hepatitis B and C in C hina
inferredcites →https://doi.org/10.1111/jgh.12718openalex-snapshot
Long‐term lamivudine treatment achieves regression of advanced liver fibrosis/cirrhosis in patients with chronic hepatitis B
inferredcites →https://doi.org/10.1111/jvh.12054openalex-snapshot
Long‐term outcome of hepatitis B virus‐related C hronic H epatitis under protracted nucleos(t)ide analogues
inferredcites →https://doi.org/10.1111/jvh.12283openalex-snapshot
Hepatocellular carcinoma risk in HB eAg‐negative chronic hepatitis B patients with or without cirrhosis treated with entecavir: HepNet.Greece cohort
inferredcites →https://doi.org/10.1111/jvh.12358openalex-snapshot
Long‐term entecavir or tenofovir disoproxil fumarate therapy in treatment‐naïve chronic hepatitis B patients in the real‐world setting
inferredcites →https://doi.org/10.1111/jvh.12971openalex-snapshot
Mortality, liver transplantation and hepatic complications in patients with treatment‐naïve chronic hepatitis B treated with entecavir vs tenofovir
inferredcites →https://doi.org/10.1128/aac.02483-13openalex-snapshot
Prior Exposure to Lamivudine Increases Entecavir Resistance Risk in Chronic Hepatitis B Patients without Detectable Lamivudine Resistance
inferredcites →https://doi.org/10.1128/aac.21.1.93openalex-snapshot
Antiviral treatment of chronic hepatitis B virus infection: pharmacokinetics and side effects of interferon and adenine arabinoside alone and in combination
inferredcites →https://doi.org/10.1136/bmjopen-2013-003265openalex-snapshot
Antiviral therapy for prevention of hepatocellular carcinoma and mortality in chronic hepatitis B: systematic review and meta-analysis
inferredcites →https://doi.org/10.1136/gutjnl-2015-309809openalex-snapshot
HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B
inferredcites →https://doi.org/10.1186/s12876-017-0572-2openalex-snapshot
Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial
inferredcites →https://doi.org/10.1200/jco.2012.48.5896openalex-snapshot
Effect of Antiviral Treatment With Nucleotide/Nucleoside Analogs on Postoperative Prognosis of Hepatitis B Virus–Related Hepatocellular Carcinoma: A Two-Stage Longitudinal Clinical Study
inferredcites →https://doi.org/10.1586/17474124.2014.909724openalex-snapshot
Current developments in nucleoside/nucleotide analogues for hepatitis B
inferredcites →https://doi.org/10.1634/theoncologist.2010-s4-05openalex-snapshot
The Incidence and Epidemiology of Hepatocellular Carcinoma: A Global and Regional Perspective
inferredcites →https://doi.org/10.2147/dddt.s126742openalex-snapshot
Tenofovir alafenamide in the treatment of chronic hepatitis B: design, development, and place in therapy
inferredcites →https://doi.org/10.31083/ph.2018.7982openalex-snapshot
Efficacy of entecavir-based rescue therapy in lamivudine-resistant chronic hepatitis B patients in China: a retrospective study
inferredcites →https://doi.org/10.3322/caac.21262openalex-snapshot
Global cancer statistics, 2012
inferredcites →https://doi.org/10.3322/caac.21338openalex-snapshot
Cancer statistics in China, 2015
inferredcites →https://doi.org/10.3350/cmh.2016.0086openalex-snapshot
Risk score model for the development of hepatocellular carcinoma in treatment-naïve patients receiving oral antiviral treatment for chronic hepatitis B
inferredcites →https://doi.org/10.4103/0974-2727.98664openalex-snapshot
Laboratory Evaluation of Three Regimens of Treatment of Chronic Hepatitis B: Tenofovir, Entecavir and Combination of Lamivudine and Adefovir
inferredcites →https://doi.org/10.5860/choice.49-1212openalex-snapshot
CDC health information for international travel: the yellow book, 2012

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4060774openalex-extracted
Cost-Effectiveness of First-Line Nucleos(T)Ide Analogs for Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy
inferred← citeshttps://doi.org/10.1001/jamanetworkopen.2022.19407openalex-snapshot
Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir Treatment for Chronic Hepatitis B Virus
inferred← citeshttps://doi.org/10.1002/1878-0261.70158openalex-snapshot
European Code Against Cancer, 5th edition – hormone replacement therapy, other common medical therapies and cancer
inferred← citeshttps://doi.org/10.1007/978-981-16-1815-4_5openalex-snapshot
Antiviral Therapy in Liver Cancer
inferred← citeshttps://doi.org/10.1007/978-981-99-6794-0_30openalex-snapshot
Hepatocellular Carcinoma (HCC) in the UAE
inferred← citeshttps://doi.org/10.1007/s00432-023-05076-4openalex-snapshot
A novel disulfidptosis-related immune checkpoint genes signature: forecasting the prognosis of hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1007/s11901-022-00588-yopenalex-snapshot
Risk of HCC in Patients with HBV, Role of Antiviral Treatment
inferred← citeshttps://doi.org/10.1007/s12072-019-10005-0openalex-snapshot
Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1016/j.cgh.2021.03.035openalex-snapshot
Reply
inferred← citeshttps://doi.org/10.1016/j.iliver.2022.08.006openalex-snapshot
Tenofovir disoproxil fumarate therapy in patients with chronic hepatitis B and advanced fibrosis or compensated cirrhosis
inferred← citeshttps://doi.org/10.1016/j.jhep.2020.06.011openalex-snapshot
Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1016/j.jhep.2021.09.017openalex-snapshot
Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments
inferred← citeshttps://doi.org/10.1016/j.jhep.2022.12.007openalex-snapshot
Hepatocellular carcinoma risk in patients with chronic hepatitis B receiving tenofovir- vs. entecavir-based regimens: Individual patient data meta-analysis
inferred← citeshttps://doi.org/10.1016/j.jhepr.2022.100623openalex-snapshot
Health inequalities in the management of chronic hepatitis B virus infection in patients from sub-Saharan Africa in high-income countries
inferred← citeshttps://doi.org/10.1016/j.puhe.2026.106387openalex-snapshot
Hepatitis B screening disparities in the United States: An implementation-focused narrative review
inferred← citeshttps://doi.org/10.1016/s2468-1253(20)30249-1openalex-snapshot
Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis
inferred← citeshttps://doi.org/10.1038/s41598-020-70433-zopenalex-snapshot
Hepatocellular carcinoma and death and transplantation in chronic hepatitis B treated with entecavir or tenofovir disoproxil fumarate
inferred← citeshttps://doi.org/10.1097/cm9.0000000000001793openalex-snapshot
Low-level viremia in nucleoside analog-treated chronic hepatitis B patients
inferred← citeshttps://doi.org/10.1097/hc9.0000000000000205openalex-snapshot
Rapid monophasic HBsAg decline during nucleic-acid polymer–based therapy predicts functional cure
inferred← citeshttps://doi.org/10.1097/mcg.0000000000001548openalex-snapshot
Differential Effectiveness of Tenofovir and Entecavir for Prophylaxis of Hepatocellular Carcinoma in Chronic Hepatitis B Patients Depending on Coexisting Cirrhosis and Prior Exposure to Antiviral Therapy
inferred← citeshttps://doi.org/10.1097/meg.0000000000001733openalex-snapshot
Comparison of the impact of tenofovir alafenamide and entecavir on declines of hepatitis B surface antigen levels
inferred← citeshttps://doi.org/10.1111/apt.16116openalex-snapshot
Five‐year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment‐naïve patients with chronic hepatitis B‐related compensated cirrhosis in Taiwan
inferred← citeshttps://doi.org/10.1111/apt.16786openalex-snapshot
Risk of hepatocellular carcinoma in treatment‐naïve chronic hepatitis B patients receiving tenofovir disoproxil fumarate versus entecavir in the United States
inferred← citeshttps://doi.org/10.1111/jcmm.70717openalex-snapshot
Clinical Features of HBV‐Related HCC in Long‐Term NAs‐Treated Versus Untreated Patients
inferred← citeshttps://doi.org/10.1111/jgh.15036openalex-snapshot
Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: A systematic review and meta‐analysis
inferred← citeshttps://doi.org/10.1111/jgh.15078openalex-snapshot
Magnitude of and prediction for risk of hepatocellular carcinoma in patients with chronic hepatitis B taking entecavir or tenofovir therapy: A systematic review
inferred← citeshttps://doi.org/10.1111/jgh.15783openalex-snapshot
Lower risk of hepatocellular carcinoma with tenofovir than entecavir treatment in subsets of chronic hepatitis B patients: an updated meta‐analysis
inferred← citeshttps://doi.org/10.1136/jitc-2024-011258openalex-snapshot
Cancer immunotherapy clinical trials to support urgently needed access in low- and middle-income countries: a report from the SITC global access and impact committee
inferred← citeshttps://doi.org/10.1159/000507253openalex-snapshot
Tenofovir Treatment Has Lower Risk of Hepatocellular Carcinoma than Entecavir Treatment in Patients with Chronic Hepatitis B: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.1177/2049936120985954openalex-snapshot
Long-term efficacy and safety of nucleos(t)ides analogues in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.1186/s12885-022-09413-7openalex-snapshot
Risk of hepatocellular carcinoma in antiviral treatment-naïve chronic hepatitis B patients treated with entecavir or tenofovir disoproxil fumarate: a network meta-analysis
inferred← citeshttps://doi.org/10.1186/s43088-022-00294-0openalex-snapshot
Effect of entecavir and tenofovir disoproxil fumarate on hepatocellular carcinoma in subjects with chronic hepatitis B: a meta-analysis
inferred← citeshttps://doi.org/10.1371/journal.pone.0327298openalex-snapshot
Tenofovir alafenamide is superior to tenofovir disoproxil fumarate and entecavir in cost-effectiveness of treatment of chronic hepatitis B in china with new volume-based procurement policy
inferred← citeshttps://doi.org/10.14218/jcth.2021.00046openalex-snapshot
Chronic Hepatitis B Infection with Low Level Viremia Correlates with the Progression of the Liver Disease
inferred← citeshttps://doi.org/10.14309/ajg.0000000000001157openalex-snapshot
Outcomes of Sequential Therapy With Tenofovir Alafenamide After Long-term Entecavir
inferred← citeshttps://doi.org/10.14309/ctg.0000000000000236openalex-snapshot
Entecavir vs Tenofovir in Hepatocellular Carcinoma Prevention in Chronic Hepatitis B Infection: A Systematic Review and Meta-Analysis
inferred← citeshttps://doi.org/10.18632/aging.202573openalex-snapshot
No difference in hepatocellular carcinoma risk in chronic hepatitis B patients treated with tenofovir vs entecavir: evidence from an updated meta-analysis
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.113openalex-snapshot
Use of tenofovir disoproxil fumarate is associated with a lower risk of hepatocellular carcinoma than entecavir in patients with chronic hepatitis B
inferred← citeshttps://doi.org/10.20517/2394-5079.2021.144openalex-snapshot
Overview of methodologies and statistical strategies in observational studies and meta-analyses on the risk of hepatocellular carcinoma in patients with chronic hepatitis B on entecavir or tenofovir therapy
inferred← citeshttps://doi.org/10.21037/hbsn-2020-3openalex-snapshot
Tenofovir vs. entecavir in reducing hepatocellular carcinoma risk in patients with chronic HBV infection?—Still an unsolved question
inferred← citeshttps://doi.org/10.21037/hbsn-23-528openalex-snapshot
The power of prevention: how tenofovir and entecavir are changing the game in hepatocellular carcinoma
inferred← citeshttps://doi.org/10.21203/rs.3.rs-2254145/v1openalex-snapshot
Tenofovir disoproxil fumarate is superior to Entecavir and Tenofovir alafenamide in Cost-Effectiveness of Treatment of Chronic Hepatitis B in China with New Volume-Based Purchasing Policy
inferred← citeshttps://doi.org/10.2147/ijgm.s472260openalex-snapshot
Daily Antiplatelets Other Than Aspirin Reduce Liver Cancer Risk but Increase Intracranial Hemorrhage Risk in Cirrhotic Patients
inferred← citeshttps://doi.org/10.3346/jkms.2021.36.e89openalex-snapshot
Entecavir versus Tenofovir for the Prevention of Hepatocellular Carcinoma in Treatment-naïve Chronic Hepatitis B Patients in Korea
inferred← citeshttps://doi.org/10.3389/fonc.2021.664794openalex-snapshot
Putative Repurposing of Lamivudine, a Nucleoside/Nucleotide Analogue and Antiretroviral to Improve the Outcome of Cancer and COVID-19 Patients
inferred← citeshttps://doi.org/10.3390/cancers14112617openalex-snapshot
Systematic Review with Meta-Analysis: Comparison of the Risk of Hepatocellular Carcinoma in Antiviral-Naive Chronic Hepatitis B Patients Treated with Entecavir versus Tenofovir: The Devil in the Detail
inferred← citeshttps://doi.org/10.3390/jcm15114021openalex-snapshot
Greater Reductions in Hepatitis B Core-Related Antigen Associated with Switching from Entecavir to Tenofovir Alafenamide Compared with Continued Entecavir Therapy: A Retrospective Observational Study
inferred← citeshttps://doi.org/10.3390/v16121890openalex-snapshot
Chronic Hepatitis B Genotype C Mouse Model with Persistent Covalently Closed Circular DNA
inferred← citeshttps://doi.org/10.3390/v17111471openalex-snapshot
Evaluation of the Efficacy of Tenofovir Alafenamide in Patients with Low-Level Viremia Under Chronic Hepatitis B Treatment
inferred← citeshttps://doi.org/10.5152/tjg.2021.20423openalex-snapshot
Comparison of the Efficacy of Entecavir and Tenofovir in Reducing Hepatocellular Carcinoma Risk in Chronic Hepatitis B Patients: A Real-Life Study in Turkey
inferred← citeshttps://doi.org/10.5495/wjcid.v9.i2.11openalex-snapshot
Towards the worldwide eradication of hepatitis B virus infection: A combination of prophylactic and therapeutic factors
inferred← citeshttps://doi.org/10.59873/vjid.v1i33.80openalex-snapshot
ĐẶC ĐIỂM LÂM SÀNG, CẬN LÂM SÀNG Ở BỆNH NHÂN VIÊM GAN VI RÚT B MẠNTIẾN TRIỂN UNG THƯ GAN NGUYÊN PHÁT TẠI BỆNH VIỆN BỆNH NHIỆT ĐỚI TRUNG ƯƠNG
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.